Compare Inovio Pharmaceuticals Inc (INO) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Kraft Heinz Co — how do they compare? Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M), while Kraft Heinz Co trades at $24.54 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 372.1× Inovio Pharmaceuticals Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | KHC | |
|---|---|---|
Market Cap | $78.55M | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $28.06 |
52-Week Low | $0.66 | $21.21 |
Enterprise Value | $49.56M | $45.55B |
Dividend Yield | — | 6.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
Kraft Heinz (KHC) trades at $24.48, down 1.81% on the day, with a bearish technical signal and mixed sentiment. The stock shows attractive valuation ratios like a P/E of 13.04 and P/B of 0.81, but fundamentals are pressured by a net loss of $5.85 billion in 2025 and negative profit margins. Recent quarters have beaten EPS estimates, and the company maintains a $0.40 quarterly dividend, though dividend sustainability concerns persist amid earnings erosion.
The outlook is cautious; while the stock appears undervalued and dividend yield is high, ongoing profit declines and sector headwinds pose risks. Analyst consensus is mixed with a $24 price target, and institutional selling adds pressure. Key catalysts include the success of CEO Cahillane's turnaround strategy, but execution risks and competitive threats remain significant hurdles for shareholder value recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
